Literature DB >> 1829656

The pharmacodynamics and pharmacokinetics of Org 9426, a new non-depolarizing neuromuscular blocking agent, in patients anaesthetized with nitrous oxide, halothane and fentanyl.

J M Wierda1, U W Kleef, L M Lambalk, W D Kloppenburg, S Agoston.   

Abstract

The pharmacodynamics and pharmacokinetics of a new non-depolarizing neuromuscular blocking agent, Org 9426, were investigated. Ten patients undergoing elective head and neck surgery and anaesthetized with nitrous oxide, halothane and fentanyl, received a bolus dose of Org 9426 (1 mg.kg-1, 3 x ED90). The isometric contractions of the adductor pollicis muscle following ulnar nerve stimulation (0.1 Hz and intermittent TOF) were measured. Blood and urine were sampled over 8 and 24 hr, respectively. Concentrations of Org 9426 and its possible metabolites in plasma and urine were determined using HPLC. Pharmacokinetic variables were calculated by iterative linear least square regression analysis. Intubation conditions were excellent one minute after administration at a neuromuscular block of 88 (13)% (Mean (CV]. Onset time until maximum block, duration until 25% recovery of twitch height, and recovery from 25 until 75% of twitch height were 1.7 (32), 53 (19) and 20 (37) min, respectively. The TOF reached a ratio of 0.7 after 87 (19) min. Half lives were 1.8 (33), 19 (34), 131 (62) min, respectively, in a three exponential decay; distribution volume at steady-state and plasma clearance were 0.264 (56) L.kg-1 and 4.0 (21) ml.kg-1.min-1, respectively. Plasma concentration at 25% recovery of the twitch height was 1.0 mg.L-1. Within 24 h, 33 (37)% of Org 9426 was excreted unchanged in the urine. Metabolites were absent both in plasma and urine. We conclude that the difference in potency between Org 9426 and vecuronium is similar to the difference between their effective concentrations.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1829656     DOI: 10.1007/BF03007578

Source DB:  PubMed          Journal:  Can J Anaesth        ISSN: 0832-610X            Impact factor:   5.063


  12 in total

1.  The neuromuscular blocking effects and pharmacokinetics of ORG 9426 and ORG 9616 in the cat.

Authors:  K Khuenl-Brady; K P Castagnoli; P C Canfell; J E Caldwell; S Agoston; R D Miller
Journal:  Anesthesiology       Date:  1990-04       Impact factor: 7.892

2.  Effects of a new neuromuscular blocking agent (Org 9426) in anaesthetized cats and pigs and in isolated nerve-muscle preparations.

Authors:  A W Muir; J Houston; K L Green; R J Marshall; W C Bowman; I G Marshall
Journal:  Br J Anaesth       Date:  1989-10       Impact factor: 9.166

3.  Intubation conditions and reversibility of a new non-depolarizing neuromuscular blocking agent, Org-NC45.

Authors:  N Krieg; L Mazur; L H Booij; J F Crul
Journal:  Acta Anaesthesiol Scand       Date:  1980-10       Impact factor: 2.105

4.  Pharmacokinetic analyses with RUGFIT: an interactive pharmacokinetic computer program.

Authors:  A H Scaf
Journal:  Biopharm Drug Dispos       Date:  1988 Sep-Oct       Impact factor: 1.627

5.  Disposition and urinary excretion of vecuronium bromide in anesthetized patients with normal renal function or renal failure.

Authors:  A F Bencini; A H Scaf; Y J Sohn; C Meistelman; A Lienhart; U W Kersten; S Schwarz; S Agoston
Journal:  Anesth Analg       Date:  1986-03       Impact factor: 5.108

6.  Comparative pharmacokinetics and dynamics of vecuronium and pancuronium in anesthetized patients.

Authors:  Y J Sohn; A F Bencini; A H Scaf; U W Kersten; S Agoston
Journal:  Anesth Analg       Date:  1986-03       Impact factor: 5.108

7.  Clinical observations on the neuromuscular blocking action of Org 9426, a new steroidal non-depolarizing agent.

Authors:  J M Wierda; A P de Wit; K Kuizenga; S Agoston
Journal:  Br J Anaesth       Date:  1990-04       Impact factor: 9.166

8.  Assay of vecuronium in plasma using solid-phase extraction, high-performance liquid chromatography and post-column ion-pair extraction with fluorimetric detection.

Authors:  J E Paanakker; J M Thio; H M Van den Wildenberg; F M Kaspersen
Journal:  J Chromatogr       Date:  1987-10-30

9.  Hepatobiliary disposition of vecuronium bromide in man.

Authors:  A F Bencini; A H Scaf; Y J Sohn; U W Kersten-Kleef; S Agoston
Journal:  Br J Anaesth       Date:  1986-09       Impact factor: 9.166

10.  Cardiovascular and neuromuscular effects of three steroidal neuromuscular blocking drugs in dogs (ORG 9616, ORG 9426, ORG 9991).

Authors:  B Cason; D G Baker; R F Hickey; R D Miller; S Agoston
Journal:  Anesth Analg       Date:  1990-04       Impact factor: 5.108

View more
  28 in total

1.  Do plasma concentrations obtained from early arterial blood sampling improve pharmacokinetic/pharmacodynamic modeling?

Authors:  T M Beaufort; J H Proost; K Kuizenga; M C Houwertjes; U W Kleef; J M Wierda
Journal:  J Pharmacokinet Biopharm       Date:  1999-04

Review 2.  Clinical pharmacokinetics of the newer neuromuscular blocking drugs.

Authors:  D P Atherton; J M Hunter
Journal:  Clin Pharmacokinet       Date:  1999-03       Impact factor: 6.447

3.  Fading responses in the evoked EMG after rocuronium in cats.

Authors:  H Shiraishi; H Suzuki; T Suzuki; N Katsumata; S Ogawa
Journal:  Can J Anaesth       Date:  1992-12       Impact factor: 5.063

4.  Full-cost determination of different levels of care in the intensive care unit. An activity-based costing approach.

Authors:  J J Doyle; J P Casciano; S R Arikian; J Mauskopf; J E Paul
Journal:  Pharmacoeconomics       Date:  1996-10       Impact factor: 4.981

Review 5.  Monitoring, new drugs, and reversal of neuromuscular blocking drugs.

Authors:  D R Bevan
Journal:  Can J Anaesth       Date:  1991-05       Impact factor: 5.063

6.  The relationship between the target effective site concentration of rocuronium and the degree of recovery from neuromuscular blockade in elderly patients.

Authors:  Xiaochong Fan; Minyu Ma; Zhisong Li; Shengkai Gong; Wei Zhang; Yuanyuan Wen
Journal:  Int J Clin Exp Med       Date:  2015-09-15

7.  Effective method of continuous rocuronium administration based on effect-site concentrations using a pharmacokinetic/pharmacodynamic model during propofol-remifentanil anesthesia.

Authors:  Takahiro Moriyama; Akira Matsunaga; Osamu Nagata; Kei Enohata; Tomomi Kamikawaji; Erika Uchino; Yuichi Kanmura
Journal:  J Anesth       Date:  2015-03-01       Impact factor: 2.078

Review 8.  Clinical pharmacokinetics of neuromuscular blocking drugs.

Authors:  S Agoston; R H Vandenbrom; J M Wierda
Journal:  Clin Pharmacokinet       Date:  1992-02       Impact factor: 6.447

Review 9.  Newer neuromuscular blocking agents: how do they compare with established agents?

Authors:  H J Sparr; T M Beaufort; T Fuchs-Buder
Journal:  Drugs       Date:  2001       Impact factor: 9.546

10.  Anesthetic practice in Japan: past, present, and future.

Authors:  Michiaki Yamakage; Akiyoshi Namiki
Journal:  J Anesth       Date:  2007-08-01       Impact factor: 2.078

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.